Exact Sciences (EXAS) closed at $57.56 in the latest trading session, marking a -1.96% move from the prior day. This change lagged the S&P 500’s daily gain of 2.14%. Meanwhile, the Dow gained 1.82%, and the Nasdaq, a tech-heavy index, added 0.12%.
Prior to today’s trading, shares of the molecular diagnostics company had lost 25.05% over the past month. This has lagged the Medical sector’s loss of 1.34% and the S&P 500’s loss of 5.01% in that time.
Investors will be hoping for strength from Exact Sciences as it approaches its next earnings release. The company is expected to report EPS of -$1.12, down 522.22% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $461.86 million, up 14.87% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$4.33 per share and revenue of $2.01 billion, which would represent changes of -24.43% and +13.51%, respectively, from the prior year.
Any recent changes to analyst estimates for Exact Sciences should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company’s business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 27.33% lower within the past month. Exact Sciences is currently sporting a Zacks Rank of #3 (Hold).
The Medical – Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 163, which puts it in the bottom 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
